1. Home
  2. MLYS vs CLM Comparison

MLYS vs CLM Comparison

Compare MLYS & CLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$29.93

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Cornerstone Strategic Value Fund Inc. New

CLM

Cornerstone Strategic Value Fund Inc. New

HOLD

Current Price

$7.49

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
CLM
Founded
2019
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.2B
IPO Year
2023
1995

Fundamental Metrics

Financial Performance
Metric
MLYS
CLM
Price
$29.93
$7.49
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$48.67
N/A
AVG Volume (30 Days)
1.8M
1.5M
Earning Date
05-06-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
37.43
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.59
$6.92
52 Week High
$47.65
$8.53

Technical Indicators

Market Signals
Indicator
MLYS
CLM
Relative Strength Index (RSI) 66.82 48.27
Support Level $25.88 $7.33
Resistance Level $31.29 $7.79
Average True Range (ATR) 1.42 0.08
MACD 0.65 0.01
Stochastic Oscillator 84.16 48.10

Price Performance

Historical Comparison
MLYS
CLM

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About CLM Cornerstone Strategic Value Fund Inc. New

Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, Consumer Staples, utilities, energy, Real Estate, materials, and other sectors.

Share on Social Networks: